Key result
Dabigatran 150 mg showed a higher risk of myocardial infarction versus warfarin (OR 1.42; 95% CI 1.07-1.88) but similar rates versus placebo, suggesting warfarin has a more protective effect.
Why the study?
Does dabigatran increase the risk of myocardial infarction compared to warfarin, enoxaparin, or placebo in patients across multiple indications?
Population
n=42,484 patients from 14 completed Phase II and III comparative trials across five different indications
Comparison
Dabigatran etexilate vs Warfarin, enoxaparin, or placebo
Design
Meta-analysis
Authors
Loading...
Warrants MI risk caution with dabigatran versus warfarin; confirms differential anticoagulant effects in Level 1 evidence.
Meta-Analysis (n=42,484)
Does dabigatran increase the risk of myocardial infarction compared to warfarin, enoxaparin, or placebo in patients across multiple indications?
Odds Ratio: 1.42 (95% CI 1.07–1.88)
While dabigatran is associated with a higher rate of myocardial infarction compared to well-controlled warfarin, it maintains a positive overall benefit-risk ratio for major cardiovascular composite endpoints.
Clemens et al. (2013) conducted a meta-analysis in Nonvalvular atrial fibrillation, venous thromboembolism, and other indications (n=42,484). Dabigatran vs. Warfarin, enoxaparin, or placebo was evaluated on Myocardial infarction (dabigatran 150 mg twice daily vs warfarin) (OR 1.42, 95% CI 1.07-1.88). Dabigatran 150 mg showed a higher risk of myocardial infarction versus warfarin (OR 1.42; 95% CI 1.07-1.88) but similar rates versus placebo, suggesting warfarin has a more protective effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: